<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035956</url>
  </required_header>
  <id_info>
    <org_study_id>RB_0004-01</org_study_id>
    <nct_id>NCT02035956</nct_id>
  </id_info>
  <brief_title>IVAC MUTANOME Phase I Clinical Trial</brief_title>
  <official_title>First-in-human Study Evaluating the Safety, Tolerability and Immunogenicity of i.n. Administration of a Personalized Vaccination With IVAC MUTANOME Vaccine w/o Initial Treatment With RBL001/RBL002 Vaccine in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioNTech RNA Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioNTech SE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical first-in-human study evaluating the safety, tolerability and immunogenicity of&#xD;
      intra-nodal administration of a personalized vaccination with IVAC MUTANOME vaccine with or&#xD;
      without initial treatment with RBL001/RBL002 vaccine in patients with advanced melanoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IVAC MUTANOME is a poly-neo-epitopic coding RNA vaccine targeting the unique mutation&#xD;
      signature of an individual patient. It is engineered on demand, provided as two&#xD;
      patient-specific RNA drug products and administered as an individual treatment.&#xD;
&#xD;
      RBL001/RBL002 and IVAC MUTANOME are naked ribonucleic acid (RNA) based recombinant vaccines&#xD;
      optimized to induce antigen-specific CD8+ and CD4+ T cell responses against melanoma&#xD;
      associated target antigens.&#xD;
&#xD;
      The two antigens are well characterized antigens in melanoma that have been previously&#xD;
      utilized with excellent safety and proven immunogenicity as vaccine targets in a number of&#xD;
      independent clinical trials.&#xD;
&#xD;
      The overall rationale of the study is to determine safety of the novel RNA-based vaccine&#xD;
      strategy and determine the number and function of vaccine-induced antigen-specific&#xD;
      immune-responses as early biomarkers for the clinical mode of action.&#xD;
&#xD;
      The IVAC MUTANOME vaccine approach is based on targeting multiple immunogenic tumour&#xD;
      mutations unique to a given patient's tumour using a poly-epitopic RNA-based vaccine&#xD;
      manufactured for use in a single patient only. Parallel to the target discovery process and&#xD;
      on demand manufacturing of IVAC MUTANOME vaccine patients with RBL001 and/ or RBL002&#xD;
      positive-tumours will receive the RBL001/RBL002 vaccine. Patients which tumours that are&#xD;
      RBL001 and RBL002 negative can also be included into the clinical study but will not receive&#xD;
      RBL001/RBL002 prior to IVAC MUTANOME. Applying this approach the RBL001/RBL002 vaccine and&#xD;
      the IVAC MUTANOME vaccine administration is expected to lead to several effects contributing&#xD;
      to their immunological (therapeutic) effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">February 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of repetitive doses</measure>
    <time_frame>up to a maximum of 189 days</time_frame>
    <description>Number of Patients with adverse events, total number of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of vaccine-induced cellular immune response,</measure>
    <time_frame>161 days</time_frame>
    <description>Determination of pharmacodynamic activity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>IVAC MUTANOME RBL001/RBL002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will be treated with the personalized IVAC MUTANOME vaccine with or without prior treatment with RBL001/RBL002 vaccine depending on expression of these two antigens. Vaccines will be administered intra-nodally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IVAC MUTANOME, RBL001/RBL002</intervention_name>
    <description>Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.</description>
    <arm_group_label>IVAC MUTANOME RBL001/RBL002</arm_group_label>
    <other_name>cancer vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Malignant Melanoma, resectable stage IIIA-C and IV (AJCC 2009 melanoma classification)&#xD;
&#xD;
          -  Patients with unresectable Malignant Melanoma stage IIIA-C in complete remission,&#xD;
             partial remission or stable disease after treatment with vemurafenib or patients with&#xD;
             slow progressive disease.&#xD;
&#xD;
          -  Malignant Melanoma, unresectable stage IV (AJCC 2009 melanoma classification) in&#xD;
             complete remission, partial remission or stable disease after treatment with&#xD;
             vemurafenib&#xD;
&#xD;
          -  All lines of treatment for malignant melanoma are accepted.&#xD;
&#xD;
          -  First line therapy for subjects not eligible or declining other first line therapies&#xD;
             after all available treatment options have been transparently disclosed (to be&#xD;
             documented in patient medical record).&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 (appendix G)&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  WBC ≥ 3x109/L&#xD;
&#xD;
          -  Haemoglobin ≥ 10 g/dl&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  LDH level &lt; 2.0 x ULN&#xD;
&#xD;
          -  Negative pregnancy test (measured by β-HCG) for females which are childbearing&#xD;
             potential&#xD;
&#xD;
          -  Suitable lymph nodes for injection using ultrasound guidance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Primary ocular melanoma&#xD;
&#xD;
          -  History (&lt; 5 years) of a second malignancy other than squamous or basal cell&#xD;
             carcinoma, non-active prostate cancer or cervical carcinoma in situ&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  Known or symptomatic pleural effusions and/or ascites&#xD;
&#xD;
          -  Known hypersensitivity to the active substance or to any of the excipients&#xD;
&#xD;
          -  A serious local infection (e.g. cellulitis, abscess) or systemic infection (e.g.&#xD;
             pneumonia, septicemia) which requires systemic antibiotic treatment within 2 weeks&#xD;
             prior to the first dose of study medication&#xD;
&#xD;
          -  Positive test for acute or chronic active hepatitis B or C infection, acute EBV or&#xD;
             acute CMV injection&#xD;
&#xD;
          -  Clinically relevant autoimmune disease&#xD;
&#xD;
          -  Systemic immune suppression:&#xD;
&#xD;
          -  HIV disease&#xD;
&#xD;
          -  Use of chronic oral or systemic steroid medication (topical or inhalational steroids&#xD;
             are permitted)&#xD;
&#xD;
          -  Other clinical relevant systemic immune suppression&#xD;
&#xD;
          -  Symptomatic congestive heart failure (NYHA 3 or 4)&#xD;
&#xD;
          -  Unstable angina pectoris&#xD;
&#xD;
          -  Radiotherapy within two weeks, myelosuppressive chemotherapy, ipilimumab and major&#xD;
             surgery within 4 weeks/28 days before the first treatment. Interferon and approved&#xD;
             BRAF inhibitors will be allowed as concurrent treatment.&#xD;
&#xD;
          -  Any investigational drug within 4 weeks/28 days or 5 half-lives depending on what&#xD;
             gives the longer range before the first treatment of this study&#xD;
&#xD;
          -  Minor surgery within 14 days before the first treatment of this study&#xD;
&#xD;
          -  Fertile males and females who are unwilling to use a highly effective method of birth&#xD;
             control (less than 1% per year, e.g. condom with spermicide, diaphragm with&#xD;
             spermicide, birth control pills, injections, patches or intrauterine device) during&#xD;
             study treatment and 28 days after the last dose of study treatment&#xD;
&#xD;
          -  Presence of a serious concurrent illness or other condition (e.g. psychological,&#xD;
             family, sociological, or geographical circumstances) that does not permit adequate&#xD;
             follow-up and compliance with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ugur Sahin, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>BioNTech RNA Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <state>AT-Wien</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautklinik und Poliklinik Universitätsmedizin der Johannes-Gutenberg Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Dermatologie, Venerologie und Allergologie UMM - Universitätsmedizin Mannheim Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVAC MUTANOME</keyword>
  <keyword>IVAC</keyword>
  <keyword>personalized therapy</keyword>
  <keyword>personalized immuno therapy</keyword>
  <keyword>RB_0004-01</keyword>
  <keyword>Ribological</keyword>
  <keyword>Melanoma</keyword>
  <keyword>cancer vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

